At a glance
WHAT IT’S REALLY ABOUT
AbbVie uses Claude to transform pharma workflows and drug discovery
- AbbVie is pursuing a value-chain AI strategy that targets priorities across discovery, development, and commercial functions to improve patient impact and operational performance.
- In drug discovery, AbbVie prioritizes AI for understanding biology, multiparameter drug optimization, indication expansion via multimodal data integration, and precision medicine starting with digital pathology.
- In clinical development, AI is used to improve trial design (criteria, adaptive designs, responder subpopulations) and to automate trial operations and regulatory/study document workflows.
- AbbVie and Anthropic highlight two flagship generative-AI tools—Genesis for sales call planning and Gaia for clinical document authoring—showing measurable efficiency gains (including ~40–60% time savings for document writing).
- Successful enterprise AI transformation is framed as a people-and-process change effort, supported by upskilling, quick-win ROI demonstrations, and empowered functional “AI champions,” plus a four-pillar partner diligence framework.
IDEAS WORTH REMEMBERING
5 ideasTreat AI as an end-to-end value-chain transformation, not isolated pilots.
AbbVie frames AI as capable of reimagining every pharma function and organizes priorities by function (discovery, development, commercial), ensuring use cases ladder up to business and patient outcomes.
Generative AI can produce measurable operational efficiencies in regulated workflows.
Gaia applies LLMs to automate study and regulatory document authoring (starting with NDA and PSUR documents), delivering roughly 40–60% time savings and scaling toward thousands of document types.
Commercial productivity can be improved with genAI embedded in existing systems.
Genesis pulls forward Salesforce-related tools to improve sales call planning, with early results indicating significant efficiency and effectiveness improvements for AbbVie’s sales reps.
Change management is as critical as model selection in large enterprises.
AbbVie emphasizes “hearts and minds” alongside process management, using organization-wide upskilling, early ROI wins, and distributed champions to drive adoption.
Quick wins can fund the broader AI roadmap.
AbbVie advises starting simple with use cases that demonstrate near-term ROI; those early results build credibility and can self-fund subsequent initiatives.
WORDS WORTH SAVING
5 quotesThere is no other technological shift that has an ability to reimagine every single function within the pharmaceutical industry, and we believe that this is truly a once-in-a-generation opportunity for us to accelerate our progress and our impact for patients.
— Sarah Nam
It's not only a technology challenge, but it's also really moving people's hearts and minds and also the process management that's needed.
— Sarah Nam
We have found that focusing on people and processes are equally as important as many of the technology decisions in truly driving an AI transformation at a large enterprise.
— Sarah Nam
[Gaia]... has led to r-roughly forty to sixty percent efficiencies in terms of time saving and writing some of these documents, uh, across AbbVie.
— Sarah Nam
I think my advice would be to start simple.
— Sarah Nam
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome